ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    BMT CTN 0901

Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN 1205)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02081248
Recruitment Status : Completed
First Posted : March 7, 2014
Results First Posted : June 1, 2018
Last Update Posted : June 1, 2018
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
Blood and Marrow Transplant Clinical Trials Network
National Marrow Donor Program
Information provided by (Responsible Party):
Medical College of Wisconsin

October 30, 2013
March 7, 2014
March 28, 2018
June 1, 2018
June 1, 2018
December 2013
August 3, 2016   (Final data collection date for primary outcome measure)
Quality of Informed Consent Part A (QuIC-A) Score [ Time Frame: Within 7 days of consent discussion ]
The primary objective of the trial is to compare objective comprehension scores on the Quality of Informed Consent (part A) instrument between subjects randomized to the ETRIC versus the standard consent arms. The QuIC-A is scored on a normalized scale from 0 to 100, with a higher score indicating a greater level of comprehension.
Comprehension [ Time Frame: Day 1 ]
The primary objective of the trial is to compare objective comprehension scores on the Quality of Informed Consent (part A) instrument between subjects randomized to the ETRIC versus the standard consent arms.
Complete list of historical versions of study NCT02081248 on ClinicalTrials.gov Archive Site
  • Quality of Informed Consent Part B (QuIC-B) Score [ Time Frame: Within 7 days of consent discussion ]
    The Quality of Informed Consent Part B measures participants' perception of their understanding of cancer clinical trials to address 13 independent domains of informed consent. The QuIC-B is scored on a normalized scale from 0 to 100, with a higher score indicating a greater level of perceived understanding.
  • Modified Deaconess Informed Consent Comprehension Test (DICCT) [ Time Frame: WIthin 7 days of consent discussion ]
    The Modified Deaconess Informed Consent Comprehension Test (DICCT) uses semi-structured interviews to assess subject's understanding of the study for which they participated in an informed consent discussion. This modification of the DICCT has 11 items, each scored from 0 to 2 (0 = incorrect, 1 = partially correct, 2 = correct). The item scores are summed to produce a total score ranging from 0 to 22. A higher score indicates a higher level of comprehension.
  • REALM-R Score [ Time Frame: Within 7 days of consent discussion ]
    The Rapid Estimate of Adult Literacy in Medicine—Revised (REALM-R) is an 8-item word recognition test to provide clinicians with a valid quick assessment of patient health literacy. The score is computed as the number of words out of 8 that the patient pronounces correctly.
  • Newest Vital Sign (NVS) Score [ Time Frame: Within 7 days of consent discussion ]
    The Newest Vital Sign is a screening tool that identifies patients at risk for low health literacy. It consists of a nutritional label accompanied by five questions about information on the label. The score is equal to the number of questions answered correctly.
  • State Trait Anxiety Inventory (STAI) Score [ Time Frame: Within 7 days of consent discussion ]
    The State Trait Anxiety Inventory (STAI) measures anxiety and distinguishes it from depressive syndromes. It has two subscales: the State Anxiety Scale evaluates the current state of anxiety, asking how respondents feel "right now," and Trait Anxiety Scale evaluating relatively stable aspects of "anxiety proneness". The STAI has 40 items, 20 items allocated to each subscale, with each item scored on a 4 point Likert scale. The subscale scores shown are averages of the items in the subscale ranging from 1.0 to 4.0, with a higher score indicating a greater level of anxiety.
  • Participant Satisfaction With Consent Process [ Time Frame: Within 7 days of consent discussion ]
    A short study specific questionnaire and selected questions from the Quality of Informed Consent (QuIC) supplement questionnaire will query participants about their overall satisfaction with the consent process, helpfulness of information provided, and comprehension of key study-specific elements of treatment. Seven questions are included, each scored on a five point Likert scale. The overall score is the average of the item scores, ranging from 1.0 to 5.0, with a higher score indicating a higher level of satisfaction.
  • Participant Information Location Time [ Time Frame: Within 7 days of consent discussion ]
    Participants are asked to identify select items within the consent document and the time taken to locate items is measured. Patients who were not able to identify a given section were assigned the maximum time allotted to find each section (180 seconds).
  • Consent Rate on Parent Trial [ Time Frame: Within 7 days of consent discussion ]
    The consent rate is the rate at which participants provided consent to participate in the parent trial.
  • Secondary Comprehension [ Time Frame: Day 1 ]
    The Quality of Informed Consent (part B) measures actual subjects understanding of cancer clinical trials to address 13 independent domains of informed consent.
  • Secondary Comprehension [ Time Frame: Day 1 ]
    The Deaconess Informed Consent Comprehension Test (DICCT) uses semi-structured interviews to assess subject's understanding of 8 core elements of disclosure for the study they have agreed to participate in.
  • State Anxiety [ Time Frame: Day 1 ]
    Trait Anxiety Inventory (STAI) measures anxiety and distinguishes it from depressive syndromes.
  • Satisfaction [ Time Frame: Day 1 ]
    Short study specific questionnaire and selected questions from the Quality of Informed Consent (QuIC) supplement questionnaire will query participants about their overall satisfaction with the consent process, helpfulness of information provided, and comprehension of key study-specific elements of treatment.
  • Information Location [ Time Frame: Day 1 ]
    Subjects are asked to identify select items within the consent document and the time taken to locate items is measured.
  • Health Literacy [ Time Frame: Day 1 ]
    The Rapid Estimate of Adult Literacy in Medicine (REALM) is a medical-word recognition and pronunciation test to determine subject's grade-equivalent reading level.
  • Health Literacy [ Time Frame: Day 1 ]
    The Newest Vital Sign (NVS) uses an ice cream container nutrition label to measure numeracy and reading comprehension.
Not Provided
Not Provided
 
Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN 1205)
Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN #1205)
The study has two parts: (1) Randomized Study to evaluate the effectiveness of ETRIC, and (2) Evaluation Study to understand barriers to implementation of ETRIC.

A two-arm, randomized study will be conducted in patients about to undergo consent discussion for participation in two large, multicenter BMT CTN clinical trials. Once they agree to participate in this Easy-to-Read Informed Consent (ETRIC) study, they will go through the consent process for the parent trial using either a standard or the ETRIC consent form. The content of both forms will be similar but the ETRIC form will incorporate a two-column format with specific attention towards enhanced readability and processability. Following the consent discussion for the BMT CTN parent trial, patients will complete assessments of health literacy, comprehension of the parent trial and satisfaction and anxiety related to the consent process. These assessments will be completed within 7 business days of the consent discussion of the parent trial.

Notes: Enrollment on the BMT CTN 0901 trial (NCT01339910) was closed to further accrual on April 18, 2014. Enrollment on the BMT CTN 1203 trial (NCT02208037) completed accrual on May 13, 2016.

Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Improve the Informed Consent Process
  • Other: Consent Form Specific Format 1
    The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
  • Other: Consent Form Specific Format 2
    The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
  • Active Comparator: Standard Consent
    This arm will receive the Consent Form Specific Format 1 'standard consent'. The standard consents are already approved and used for the BMT CTN 0901, 1101, 1203, and 1301 trials.
    Intervention: Other: Consent Form Specific Format 1
  • Experimental: Easy-to-Read Informed Consent
    This arm will receive the Consent Form Specific Format 2 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent (ETRIC) is the newly approved consent.
    Intervention: Other: Consent Form Specific Format 2
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
198
160
August 3, 2016
August 3, 2016   (Final data collection date for primary outcome measure)

Inclusion and exclusion criteria for the ETRIC randomized study will be the same as the eligibility criteria for the BMT CTN parent studies. Please refer to BMTCTN0901 (NCT01339910) Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome, BMTCTN1101 (NCT01597778) Double Cord Versus Haploidentical, BMTCTN1203 (NCT02208037) Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls, and BMTCTN1301 (NCT02345850) Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease for detailed eligibility criteria.

Notes: Enrollment on the BMT CTN 0901 trial (NCT01339910) was closed to further accrual on April 18, 2014. Enrollment on the BMT CTN 1203 trial (NCT02208037) completed accrual on May 13, 2016.

Additional inclusion criteria specific for the ETRIC study will include:

  1. Adult patients (≥ 18 years)
  2. Speaking and reading proficiency in English (as most of this study's instruments have not been translated and validated in languages other than English)
  3. Willing and able to provide informed consent
  4. Stated willingness to comply with study procedures and reporting requirements

Exclusion Criteria: N/A

Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT02081248
BMTCTN1205
2U10HL069294-11 ( U.S. NIH Grant/Contract )
5U24CA076518 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Plan to Share IPD: Yes
Plan Description: Findings will be published in a manuscript.
Time Frame: Within 6 months of official study closure at participating sites.
Access Criteria: Available to the public
URL: https://biolincc.nhlbi.nih.gov/home/
Medical College of Wisconsin
Medical College of Wisconsin
  • National Heart, Lung, and Blood Institute (NHLBI)
  • National Cancer Institute (NCI)
  • Blood and Marrow Transplant Clinical Trials Network
  • National Marrow Donor Program
Study Director: Mary Horowitz, MD Center for International Blood and Marrow Transplant Research
Medical College of Wisconsin
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP